Daily Roundup

TLG.ASX ENN.ASX SMN.ASX CUV.ASX FPR.ASX

Talga Graphite Mine Awarded EU Strategic Project Status

Talga Group Ltd's natural graphite mine in Sweden has been awarded Strategic Project status under the European Commission's Critical Raw Materials (CRM) Act. This landmark recognition underscores the project's strategic value for Europe to secure its battery materials supply chain and significantly enhances Talga's pathway to finalizing project financing and development.

The CRM Act, enacted to bolster the EU's autonomy in critical raw materials essential for clean energy technologies, grants Strategic Projects a range of benefits for Talga. This includes improved access to financing, enhanced appeal to partners and customers, and expedited permitting processes. Talga's Vittangi Anode Project aims to produce 19,500 tonnes per annum of TalNode®-C, a natural graphite battery anode material derived from the company's 100% owned natural graphite resources in Sweden. Key advantages of the project include a low emission footprint, vertical integration of the mine-to-anode supply chain, and a resource base that supports expansion to over 100,000 tonnes per annum.

Elanor Investors Group Provides Market Update

Elanor Investors Group (ASX: ENN) is continuing to execute its strategy to stabilize the business and provides an update on its balance sheet stabilization and the Challenger Life Mandate. The Group remains focused on stabilizing the balance sheet and closely managing the working capital requirements of the business as the asset realisation program is progressed.

The company is negotiating prospective amendments to the terms of Elanor's $40 million Corporate Notes with Keyview (the Group's senior secured financier) and the arranger of the Notes, in preparation for the issue of a Circulating Resolution for consideration by Noteholders. Elanor is also providing regular updates to Challenger Life Company on the progress of its business stabilization.

Revised FY25 Forecast - Strong H2 Growth & Market Resilience

Structural Monitoring Systems Plc (ASX: SMN) announces a revised forecast for FY25 following its Interim Financial Report for the half-year ended 31 December 2024. Revenue forecast for FY25 is now $29.6M, with H2 FY25 revenue forecasted at $17.1M, an annualized run rate of $34.2M. Adjusted EBITDA forecast for FY25 is now $5.0M, down from September 2024 forecast of $7.6M but up 105% on FY24 Adjusted EBITDA of $2.5M.

The company remains confident in the continued progress of its innovation pipeline and is evaluating new product investments in Audio Systems and Radios, as well as acquisitions in Avionics and Structural Health Monitoring.

Positive Preliminary Results for PRENUMBRA Instant in Stroke Patients

Clinuvel Pharmaceuticals Ltd has released positive preliminary results from its CUV803 study investigating the use of its drug afamelanotide (PRENUMBRA® Instant) in the treatment of arterial ischaemic stroke (AIS) patients ineligible for standard of care intravenous thrombolysis (IVT) or endovascular thrombectomy (EVT).

The study enrolled nine adult patients with mild, moderate, and moderate-to-severe AIS, who were administered PRENUMBRA® Instant daily for up to five days. The primary endpoint was to evaluate the safety of afamelanotide, which was shown to be well tolerated. Secondary endpoints evaluated the impact of afamelanotide on neurological functions, with eight out of nine patients (88.9%) demonstrating an improvement in initial stroke symptoms and neurological disability by day 42.

FleetPartners Group Provides Business Update

FleetPartners Group Limited (ASX:FPR) has provided an update on its business activities. The company has reached the $30 million buy-back amount authorized by the Board for the first half of fiscal year 2025 (1H25). The Accelerate program, launched in FY23, has been successfully completed, with the new operating system now live in Australia. This is expected to deliver at least $6 million in annualized cost savings, with approximately half of the savings benefiting FY25 operating expenses and the full-year effect to benefit FY26.

For the year-to-date period ended 28 February 2025 (YTD25), the business has maintained good earnings momentum, with Group performance largely consistent with the 1Q25 trading update. The Group expects NPATA for 1H25 to be in the range of $37.5 - $39.5 million.